Science Explorer Back to mapMap
Discussion
Institution · Multiple Sclerosis Foundation

Most cited papers from Multiple Sclerosis Foundation

Multiple Sclerosis Foundation

What are the most cited papers from Multiple Sclerosis Foundation?

The most cited paper from Multiple Sclerosis Foundation is "Incidental MRI anomalies suggestive of multiple sclerosis" (Darin T. Okuda, Ellen M. Mowry, Ashkawn Beheshtian et al., 2008), with 641 citations. Next come "Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis" (464) and "Recommendations for cognitive screening and management in multiple sclerosis care" (412).

Showing 50 of 59 papers. Every paper with more than 46 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Incidental MRI anomalies suggestive of multiple sclerosis Darin T. Okuda, Ellen M. Mowry, Ashkawn Beheshtian et al. · Neurology 10 Dec 2008 641
2 Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti et al. · Annals of Neurology Open access 22 Jan 2021 464
3 Recommendations for cognitive screening and management in multiple sclerosis care Rosalind C. Kalb, Meghan L. Beier, Ralph H. B. Benedict et al. · Multiple Sclerosis Journal Open access 10 Oct 2018 412
4 Cognitive dysfunction in multiple sclerosis: a review of recent developments Julie A. Bobholz, Stephen M. Rao · Current Opinion in Neurology Jun 2003 380
5 Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course Rosalind C. Kalb, Theodore R. Brown, Susan B. Coote et al. · Multiple Sclerosis Journal Open access 23 Apr 2020 338
6 Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis Jack H. Simon et al. · Annals of Neurology 1998 335
7 Inflammatory intrathecal profiles and cortical damage in multiple sclerosis Roberta Magliozzi, Owain W. Howell, Richard S. Nicholas et al. · Annals of Neurology Open access 8 Mar 2018 300
8 Quality of Life in Multiple Sclerosis Richard A. Rudick · Archives of Neurology Dec 1992 248
9 Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies Maria Pia Sormani et al. · EBioMedicine Open access119 authors 22 Sep 2021 225
10 Defining interferon β response status in multiple sclerosis patients Richard A. Rudick, Jar‐Chi Lee, Jack H. Simon et al. · Annals of Neurology 9 Sep 2004 218
11 Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) D Goodkin, Diane L. Cookfair, Karl E. Wende et al. · Neurology Apr 1992 214
12 Management of Multiple Sclerosis Richard A. Rudick, Jeffrey Allen Cohen, Bianca Weinstock‐Guttman et al. · New England Journal of Medicine 27 Nov 1997 203
13 Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation? Richard M. Ransohoff, Marie Tani · Trends in Neurosciences Review Apr 1998 195
14 Distributed changes in default-mode resting-state connectivity in multiple sclerosis Simona Bonavita, Antonio García Gallo, Rosaria Sacco et al. · Multiple Sclerosis Journal 14 Jan 2011 191
15 Genotype–Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures Darin T. Okuda, Radhika Srinivasan, Jorge R. Oksenberg et al. · Brain Open access 20 Nov 2008 175
16 Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study Emilio Portaccio et al. · Brain Open access 23 Mar 2022 162
17 Improving quality of life in multiple sclerosis: an unmet need. Howard Zwibel, Jennifer Smrtka · PubMed May 2011 151
18 Combination therapy in multiple sclerosis Devon S. Conway, Jeffrey Allen Cohen · The Lancet Neurology 17 Feb 2010 123
19 A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients L. Jacobs et al. · Multiple Sclerosis Journal Jun 1995 118
20 Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial Antonio Uccelli et al. · The Lancet Neurology 22 Oct 2021 116
21 Observational Gait Assessments in People With Neurological Disorders: A Systematic Review María Dolores Gor-García-Fogeda, Roberto Cano‐de‐la‐Cuerda, María Carratalá‐Tejada et al. · Archives of Physical Medicine and Rehabilitation Review 5 Aug 2015 113
22 Biomarkers Indicative of Blood‐Brain Barrier Disruption in Multiple Sclerosis Emmanuelle L. Waubant · Disease Markers Open access 2006 111
23 The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool Richard A. Rudick, Deborah M. Miller, François Béthoux et al. · Journal of Visualized Experiments Open access 30 Jun 2014 108
24 Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis Marco Cosentino, Mauro Zaffaroni, Franca Marino et al. · Journal of Neuroimmunology Dec 2002 107
25 Symptom management in multiple sclerosis Randall T. Schapiro · Annals of Neurology 1994 102
26 Interferon Beta-1a in Children with Multiple Sclerosis is Well Tolerated E. Waubant, Jack Hietpas, Thomas M. Stewart et al. · Neuropediatrics Aug 2001 96
27 Clonal expansion of myelin basic protein‐reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence Caroline D. B. Vandevyver, Nadja Mertens, Peter J. van den Elsen et al. · European Journal of Immunology Apr 1995 93
28 Cytokine Secretion by Multiple Sclerosis Monocytes Richard A. Rudick · Archives of Neurology Mar 1992 84
29 Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy Maria Pia Sormani et al. · EBioMedicine Open access119 authors 5 May 2022 83
30 Adaptive vs. non-adaptive cognitive training by means of a personalized App: a randomized trial in people with multiple sclerosis Ludovico Pedullà, Giampaolo Brichetto, Andrea Tacchino et al. · Journal of NeuroEngineering and Rehabilitation Open access 4 Oct 2016 83
31 An ImmunoChip study of multiple sclerosis risk in African Americans Noriko Isobe et al. · Brain Open access 28 Mar 2015 80
32 Intolerance of Uncertainty Kevin N. Alschuler, Meghan L. Beier · International Journal of MS Care Open access 14 Jan 2015 78
33 The Potential for Vigabatrin‐Induced Intramyelinic Edema in Humans Jeffrey A. Cohen, Robert S. Fisher, Mitchell Brigell et al. · Epilepsia Feb 2000 75
34 Glucocorticosteroid therapy for multiple sclerosis: A critical review Peter-Brian Andersson, Donald E. Goodkin · Journal of the Neurological Sciences Sep 1998 73
35 The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity Roberta Magliozzi, Antonio Scalfari, Anna Isabella Pisani et al. · Annals of Neurology 17 May 2020 70
36 The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis Pavan Bhargava, Sandra D. Cassard, Sonya Ulrike Steele et al. · Contemporary Clinical Trials 12 Oct 2014 70
37 Epidemiology of multiple sclerosis in south-western Sardinia Eleonora E. Cocco, Claudia Sardu, Rita Massa et al. · Multiple Sclerosis Journal 7 Jun 2011 69
38 Patient centered decision making: Use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices Leslie Wilson, Aimee Loucks, Christine T. Bui et al. · Journal of the Neurological Sciences 23 Jun 2014 69
39 “Better explanations” in multiple sclerosis diagnostic workup Massimiliano Calabrese et al. · Neurology Open access 2 May 2019 68
40 Multiple sclerosis registries in Europe – An updated mapping survey Anna Glaser et al. · Multiple Sclerosis and Related Disorders Open access 3 Oct 2018 68
41 Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial Anthony Feinstein et al. · The Lancet Neurology Open access 20 Sep 2023 67
42 Do Chemokines Mediate Inflammatory Cell Invasion of the Central Nervous System Parenchyma? Marie Tani, Richard M. Ransohoff · Brain Pathology Open access Apr 1994 67
43 MRI and Brainstem Auditory Evoked Potential Evidence of Eighth Cranial Nerve Involvement in Multiple Sclerosis Roberto Bergamaschi, Alfredo Romani, F. Zappoli et al. · Neurology 1997 65
44 Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis Damiano Baroncini et al. · JAMA Neurology Open access 3 May 2021 63
45 Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics Richard A. Rudick · Archives of Neurology Sep 1999 62
46 Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) Silvia Messina et al. · PLoS ONE Open access Aug 2017 58
47 Dramatic rebounds of MS during pregnancy following fingolimod withdrawal Giovanni Novi, Angelo Ghezzi, Matteo Pizzorno et al. · Neurology Neuroimmunology & Neuroinflammation Open access 28 Jul 2017 57
48 Diagnostic Criteria for Multiple Sclerosis Research Involving Multiply Affected Families Donald E. Goodkin, Teresa H. Doolittle, S. S. Hauser et al. · Archives of Neurology Aug 1991 57
49 Unmet care needs of people with a neurological chronic disease: a cross-sectional study in Italy on Multiple Sclerosis Michela Ponzio, Andrea Tacchino, Paola Zaratin et al. · European Journal of Public Health Open access 30 Mar 2015 56
50 Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters Claudio Gasperini, Mark A. Horsfield, John W. Thorpe et al. · Journal of Magnetic Resonance Imaging Jul 1996 56

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.